FMOC-<wbr/>L-<wbr/>Leucine

FMOC-L-Leucine

CAT N°: 10004888
Price:

From 29.00 24.65

Peroxisome proliferator-activated receptor ? (PPAR?) isoforms heterodimerize with retinoic X receptors to modulate gene expression related to adipocyte differentiation, fatty acid uptake and storage, and glucose metabolism.{18294} Natural agonists of PPAR? include fatty acids (e.g., linoleic acid and 15-deoxy-?12,14-prostaglandin J2), while thiazolidinediones (e.g., rosiglitazone and pioglitazone) are potent synthetic agonists.{18295,18296} FMOC-L-leucine is a partial agonist of PPAR?.{11781,18295} It activates PPAR? with a lower potency (Ki = 15 versus 0.035 µM) but a similar maximal efficacy compared to rosiglitazone.{11781} FMOC-L-leucine improves insulin resistance in normal, diet-induced glucose-intolerant and in diabetic db/db mice, yet has reduced adipogenic activity.{11781} As a result, it is classified as a selective PPAR? modulator (SPPARM), capable of producing insulin-sensitizing effects while minimizing side effects associated with full agonists.{18295}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-leucine
  • Correlated keywords
    • peroxisome proliferator-activated proliferator activated receptors activates PPAR PPARg PPAR-g PPARgamma PPAR.gamma. PPAR-gamma PPAR-.gamma. PPAR? PPAR-? PPAR ? adipocytes differentiation fatty acids uptake glucose metabolism agonist partial insulin resistance diabetes adipogenesis NPC15199 NSC334290 NPC-15199 NSC-334290 Leucine L-Isomer Leucine L Isomer L-Isomer Leucine L-LeucineLeucine
  • Product Overview:
    Peroxisome proliferator-activated receptor ? (PPAR?) isoforms heterodimerize with retinoic X receptors to modulate gene expression related to adipocyte differentiation, fatty acid uptake and storage, and glucose metabolism.{18294} Natural agonists of PPAR? include fatty acids (e.g., linoleic acid and 15-deoxy-?12,14-prostaglandin J2), while thiazolidinediones (e.g., rosiglitazone and pioglitazone) are potent synthetic agonists.{18295,18296} FMOC-L-leucine is a partial agonist of PPAR?.{11781,18295} It activates PPAR? with a lower potency (Ki = 15 versus 0.035 µM) but a similar maximal efficacy compared to rosiglitazone.{11781} FMOC-L-leucine improves insulin resistance in normal, diet-induced glucose-intolerant and in diabetic db/db mice, yet has reduced adipogenic activity.{11781} As a result, it is classified as a selective PPAR? modulator (SPPARM), capable of producing insulin-sensitizing effects while minimizing side effects associated with full agonists.{18295}

We also advise you